Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANARI: Switching from Aflibercept to Ranibizumab in Wet AMD
NCT02634970Phase 4Withdrawn
- Sponsor
- Novartis
- Start
- Mar 2016
- Primary completion
- Dec 2017
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 4 trial of ranibizumab in exudative macular degeneration, sponsored by Novartis. Planned start Mar 2016; status: withdrawn.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT02634970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02634970.